Nomura Asset Management Co. Ltd. acquired a new position in Spark Therapeutics Inc (NASDAQ:ONCE) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 7,000 shares of the biotechnology company’s stock, valued at approximately $360,000.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Public Employees Retirement Association of Colorado acquired a new stake in shares of Spark Therapeutics during the fourth quarter worth $163,000. Aperio Group LLC raised its position in shares of Spark Therapeutics by 29.2% during the fourth quarter. Aperio Group LLC now owns 3,972 shares of the biotechnology company’s stock worth $204,000 after purchasing an additional 898 shares during the period. Teacher Retirement System of Texas acquired a new stake in shares of Spark Therapeutics during the third quarter worth $225,000. Prudential Financial Inc. acquired a new stake in shares of Spark Therapeutics during the third quarter worth $239,000. Finally, Commonwealth Equity Services Inc acquired a new stake in shares of Spark Therapeutics during the third quarter worth $257,000.
Spark Therapeutics stock opened at $67.51 on Monday. Spark Therapeutics Inc has a twelve month low of $41.06 and a twelve month high of $91.75.
A number of brokerages have recently issued reports on ONCE. Credit Suisse Group reaffirmed an “outperform” rating and set a $75.00 target price (up from $61.00) on shares of Spark Therapeutics in a research report on Thursday, March 8th. ValuEngine raised Spark Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Thursday, March 1st. Raymond James Financial set a $66.00 target price on Spark Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, February 21st. BMO Capital Markets set a $64.00 target price on Spark Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, February 21st. Finally, Sanford C. Bernstein reaffirmed a “buy” rating and set a $60.00 target price (down from $71.00) on shares of Spark Therapeutics in a research report on Wednesday, February 21st. They noted that the move was a valuation call. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and sixteen have given a buy rating to the stock. Spark Therapeutics currently has an average rating of “Buy” and a consensus price target of $70.58.
WARNING: This news story was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at https://stocknewstimes.com/2018/03/19/7000-shares-in-spark-therapeutics-inc-once-purchased-by-nomura-asset-management-co-ltd.html.
About Spark Therapeutics
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Want to see what other hedge funds are holding ONCE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Spark Therapeutics Inc (NASDAQ:ONCE).
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.